Form 4 Filing: Collins Helen Louise Acquires (Grant) shares of $KURA
Market Price Activity
HillSignal AI Analytical Report
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Collins Helen Louise, holds the title of Director at Kura Oncology, Inc..
On 2026-06-04, the insider transacted 35,000 shares.This transaction is a non-open-market event (such as a stock grant or option exercise) with a reported price per share of $0.00.
**Transaction:** grant of 35,000 shares by Collins Helen Louise (Director). **Strategic Implications (Investor Edge):** This grant is routine compensation for a director and carries no actionable signal about the company's prospects or insider conviction. Investors should not interpret this as bullish or bearish. **Key Takeaways:** - The transaction is a grant, not an open market purchase, so it lacks the conviction signal of a discretionary buy. - The insider is a director, not a C-suite executive, reducing the significance of the trade. - No price or value was reported, typical for grants, making it impossible to assess the insider's valuation view.
Verified Multi-Source Index
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.